A Test of Highly Optimized Tolerance Reveals Fragile Cell-Cycle Mechanisms Are Molecular Targets in Clinical Cancer Trials
Satyaprakash Nayak, Saniya Salim, Deyan Luan et al. · 2008
Read A Test of Highly Optimized Tolerance Reveals Fragile Cell-Cycle Mechanisms Are Molecular Targets in Clinical Cancer Trials by Satyaprakash Nayak, Saniya Salim, Deyan Luan et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0002016.txt.
Description
Satyaprakash Nayak and co-authors tested a theory of robust design against cancer data, in a 2008 PLOS ONE study. Living systems are robust: they keep working when conditions shift. The flip side, fragility, means a small nudge can cause total failure. A theory called highly optimized tolerance says systems tuned hard for one setting hide such fragile points.
The team tested that theory on the cell cycle, the steps by which cells divide. They report that fragile cell-cycle steps match the targets hit in clinical cancer trials. If fragility maps to drug targets, the theory could help pick the next targets on purpose.
Catalog record
| CREATOR | Satyaprakash Nayak, Saniya Salim, Deyan Luan et al. |
|---|---|
| YEAR | 2008 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 65 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0002016